{
    "nct_id": "NCT01374438",
    "title": "A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2014-11-05",
    "description_brief": "This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease. Safety and tolerability of MSDC-0160 in this population will also be studied. These results will be used to design larger studies of MSDC-0160 in persons with mild Alzheimer's disease.",
    "description_detailed": "The specific objective is to examine the feasibility of conducting future large scale studies on the efficacy of MSDC-0160 in persons with mild Alzheimer's disease. Efficacy and safety will be assessed as follows:\n\n1. Estimate the effect size of 150 mg daily MSDC-0160 versus placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis. The a priori regions of interest (ROI) will include five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex.\n2. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in brain glucose utilization, using FDG-PET voxel-based analysis.\n3. Estimate the effect size of MSDC-0160 treatment versus placebo on 3-month change in cognitive function as determined by global cognitive function on a neuropsychological battery of 19 tests.\n4. Estimate the effect size of MSDC-0160 versus placebo on 3-month change in cognitive function as determined by the ADAS-Cog subscale.\n5. Estimate the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale.\n6. Explore whether baseline levels of peripheral inflammatory biomarkers (HMW adiponectin, TNF\u03b1, IL-6, hsCRP, and FFA) or genotypes including, but not limited to, the apolipoprotein \u03b54 allele explain the heterogeneity in baseline level of brain glucose utilization and, in MSDC-0160 users, 3-month brain glucose utilization.\n7. Explore whether changes in peripheral inflammatory biomarkers correlate with changes in 3-month brain glucose utilization in MSDC-0160 users.\n8. Investigate the safety of MSDC-0160 versus placebo using reports of early study termination and adverse events.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "MSDC-0160 Capsules",
                    "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                },
                {
                    "id": "FG001",
                    "title": "Placebo Capsules",
                    "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "16"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "13"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "16"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "13"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "All randomized subjects completed the full study and are included in the analysis.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "MSDC-0160 Capsules",
                    "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                },
                {
                    "id": "BG001",
                    "title": "Placebo Capsules",
                    "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "16"
                        },
                        {
                            "groupId": "BG001",
                            "value": "13"
                        },
                        {
                            "groupId": "BG002",
                            "value": "29"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72.3",
                                            "spread": "8.8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "71.0",
                                            "spread": "8.0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "71.7",
                                            "spread": "8.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "16"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "11"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "25"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Presence of an Apolipoprotein E e4 allele",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "Apo E e4 allele present",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Apo E e4 allelle absent",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "10"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Mini-Mental State Examination Score",
                    "description": "Screening Mini-Mental State Examination Score, Mean (SD). Possible scores range between 0 and 30. Scores \u226527 indicate normal cognition, 19-24 indicate mild impairment, 10-18 indicate moderate impairment, and scores \u22649 indicate severe impairment.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "units on a scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "22.8",
                                            "spread": "2.4"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "25.2",
                                            "spread": "2.1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "23.9",
                                            "spread": "2.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum",
                    "description": "Investigate the effect of 150 mg daily MSDC-0160 vs placebo on 3-month change in brain glucose utilization using FDG-PET pre-specified regions of interest analysis referenced to cerebellum, including five bilateral regions: posterior cingulate, parietal cortex (angular gyrus), lateral temporal cortex, medial temporal cortex, and anterior cingulate-medial frontal cortex. Results are reported as Standardized Uptake Value Ratios. A change from baseline in the metabolic rate of glucose that is \u22650 indicates maintenance of brain glucose utilization, whereas values \\<0 indicate a decline in brain glucose utilization.",
                    "populationDescription": "Intent-to-treat",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Ratio",
                    "timeFrame": "Days 1(baseline) and 91",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MSDC-0160 Capsules",
                            "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo Capsules",
                            "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Posterior cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.01",
                                            "spread": "0.03"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.02",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Parietal cingulate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.01",
                                            "spread": "0.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.03",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Lateral temporal cortex",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.00",
                                            "spread": "0.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.02",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Medial temporal cortex",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.01",
                                            "spread": "0.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.01",
                                            "spread": "0.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Ant. cing.-frontal cortex",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.00",
                                            "spread": "0.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.03",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Global Cognitive Function Tests",
                    "description": "Change from baseline in cognitive function, as determined by global cognitive function on a neuropsychological battery of 19 tests, following 3 months treatment with MSDC-0160 versus placebo. A summary measure of global cognitive function was constructed by converting raw scores from 19 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "z-scores",
                    "timeFrame": "Days 1 (baseline) and 91",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MSDC-0160 Capsules",
                            "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo Capsules",
                            "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.06",
                                            "spread": "0.11"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.03",
                                            "spread": "0.59"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale",
                    "description": "Alzheimer's Disease Assessment Scale - Cognitive Subscale, an assessment of cognitive ability. Scores on 11 individual tasks were summed to produce the reported total score, with a possible range of 0 (no impairment) to 70 (severe impairment).",
                    "populationDescription": "One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the ADAS-Cog tests at both study time points.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Days 1 (baseline) and 91",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MSDC-0160 Capsules",
                            "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo Capsules",
                            "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "15"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "11"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.69",
                                            "spread": "3.62"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.21",
                                            "spread": "2.87"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale",
                    "description": "Estimate of the effect of 3-months of MSDC-0160 treatment versus placebo on a 9-item executive function scale. A summary measure of executive function was constructed by converting raw scores from 9 individual tests into z-scores as described by Bennett DA, et al., The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort, Neuroepidemiology. 2005;25(4):163-175.",
                    "populationDescription": "One subject in the MSDC-0160 group and 2 subjects in the placebo group were not able to complete the executive function tests at both study time points.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "z-score",
                    "timeFrame": "Days 1 (baseline) and 91",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MSDC-0160 Capsules",
                            "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo Capsules",
                            "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "15"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "11"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.04",
                                            "spread": "0.25"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.00",
                                            "spread": "0.45"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks",
                    "description": "Estimate the effect of 150 mg daily MSDC-0160 versus placebo on levels of high molecular weight adiponectin. Increases in HMW adiponectin suggest improved insulin sensitivity.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "micromol/L",
                    "timeFrame": "Days 1(baseline) and 91",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "MSDC-0160 Capsules",
                            "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days"
                        },
                        {
                            "id": "OG001",
                            "title": "Placebo Capsules",
                            "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "16"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "13"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17822",
                                            "spread": "10940"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "795",
                                            "spread": "4477"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "Collection of safety data began in August 2011, when the first subject was randomized, and continued until March 19, 2013, when all 29 subjects had completed all study activities.",
            "description": "Subjects were asked to report any adverse events during each study visit.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "MSDC-0160 Capsules",
                    "description": "MSDC tablets contained in #00 capsules\n\nMSDC-0160: MSDC-0160 150 mg capsules given once daily for 90 days",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 16,
                    "otherNumAffected": 7,
                    "otherNumAtRisk": 16
                },
                {
                    "id": "EG001",
                    "title": "Placebo Capsules",
                    "description": "Placebo tablets contained in #00 capsules\n\nPlacebo: Placebo capsules given once daily for 90 days",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 13,
                    "otherNumAffected": 5,
                    "otherNumAtRisk": 13
                }
            ],
            "seriousEvents": [
                {
                    "term": "Pneumonia",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Diarrhea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 3,
                            "numAffected": 3,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Peripheral Edema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Skin Laceration",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Hypoechoic nodule",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Pain in hip",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Depression",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Scrotal varicose vein rupture",
                    "organSystem": "Reproductive system and breast disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Nose bleed",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Patent foramen ovale",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "QTcB elevation",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Cognitive decline, subjective",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.o",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                },
                {
                    "term": "Syncope, vasovagal",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 16
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 13
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "LTE60",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Dr. Jerry Colca",
                "organization": "Metabolic Solutions Development Company",
                "email": "jcolca@msdrx.com",
                "phone": "269.343.8732"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "MSDC-0160 (mTOT-modulating insulin sensitizer; small-molecule)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests MSDC-0160, described in the literature as a small-molecule mTOT (mitochondrial target of thiazolidinediones) modulating insulin sensitizer intended to alter brain glucose metabolism \u2014 i.e., targeting a metabolic/pathophysiologic mechanism rather than purely symptomatic cognition enhancement. \ue200cite\ue202turn0search8\ue202turn0search2\ue201.",
        "Act (extracted details & classification): Key trial details \u2014 MSDC-0160 150 mg once daily for 90 days versus placebo with FDG-PET measures of brain glucose utilization and cognitive assessments in mild AD; safety/tolerability also assessed. Because MSDC-0160 is a small-molecule insulin-sensitizing drug developed to modulate a disease-related metabolic target (mTOT) and to affect AD-related brain metabolism, it best fits the 'disease-targeted small molecule' category. \ue200cite\ue202turn0search3\ue202turn0search8\ue201.",
        "Web search sources (supporting evidence): PubMed/PMC article reporting the AD FDG-PET study and describing MSDC-0160 as an mTOT-modulating insulin sensitizer; phase IIb/type 2 diabetes clinical pharmacology paper describing MSDC-0160 pharmacology and relation to thiazolidinediones; the clinical trial registry entry for the 3-month MSDC-0160 AD feasibility study. \ue200cite\ue202turn0search8\ue202turn0search2\ue202turn0search3\ue201.",
        "Reflect: The mechanism (insulin-sensitizer acting on mitochondrial mTOT) and the trial goal (change brain glucose utilization and cognition) indicate a disease-directed metabolic intervention rather than a symptomatic cognitive enhancer or neuropsychiatric treatment. No evidence this is a biologic (e.g., antibody or vaccine) or solely symptomatic agent, so 'disease-targeted small molecule' is the most accurate category. Minor ambiguity: MSDC-0160 was originally developed for metabolic disease (diabetes), so one could argue it's repurposing rather than an AD-pathology-specific agent \u2014 however its proposed central action on brain glucose metabolism justifies classifying it as a disease-targeted small molecule for AD. \ue200cite\ue202turn0search1\ue202turn0search8\ue201."
    ],
    "agent_type": "J) Metabolism and Bioenergetics",
    "explanation_agent": [
        "Reason: The trial drug MSDC-0160 is described in the literature as an mTOT (mitochondrial target of thiazolidinediones)\u2013modulating insulin sensitizer intended to alter mitochondrial handling of pyruvate and cellular bioenergetics, and the trial's primary outcome is change in brain glucose utilization by FDG\u2011PET \u2014 a metabolic/bioenergetic mechanism rather than an amyloid/tau or purely symptomatic mechanism. \ue200cite\ue202turn0search0\ue202turn0search1\ue201.",
        "Act: Extracted details \u2014 MSDC-0160 (small\u2011molecule mTOT modulator/insulin sensitizer) 150 mg once daily for 90 days vs placebo; FDG\u2011PET measures of brain glucose utilization and cognition in mild AD; safety/tolerability assessed. Because the agent targets mitochondrial metabolism/insulin\u2011sensitive metabolic pathways to modify brain glucose utilization, it best fits CADRO category J) Metabolism and Bioenergetics. \ue200cite\ue202turn0search3\ue202turn0search4\ue201.",
        "Reflect: This classification aligns with CADRO definitions \u2014 the intervention targets cellular/metabolic pathways (mitochondrial pyruvate handling and insulin\u2011sensitive bioenergetics) and aims to change brain glucose metabolism. It is not primarily an anti\u2011amyloid or anti\u2011tau agent, nor a symptomatic neurotransmitter receptor drug, so J is the most specific fit. Note: MSDC\u20110160 was developed for metabolic disease (type 2 diabetes) and is being repurposed for AD via metabolic mechanisms; that supports rather than contradicts the Metabolism/Bioenergetics classification. \ue200cite\ue202turn0search1\ue202turn0search0\ue201.",
        "Web search results (supporting evidence cited):",
        "\u2022 Clinical Pharmacology & Therapeutics phase IIb description of MSDC\u20110160 as an mTOT\u2011modulating insulin sensitizer and discussion of mitochondrial mechanism. \ue200cite\ue202turn0search0\ue201.",
        "\u2022 PubMed entry for the phase IIb/type 2 diabetes study describing MSDC\u20110160 pharmacology and mTOT mechanism. \ue200cite\ue202turn0search1\ue201.",
        "\u2022 Clinical trial registry / trial summary for the 3\u2011month FDG\u2011PET MSDC\u20110160 Alzheimer\u2019s feasibility study (trial NCT01374438 / ClinConnect summary). \ue200cite\ue202turn0search3\ue201.",
        "\u2022 PubMed abstract/publication reporting the evaluation of MSDC\u20110160 in patients with mild AD (FDG\u2011PET results and cognitive measures). \ue200cite\ue202turn0search4\ue201.",
        "\u2022 Trial listings/aggregators (ClinicalTrialsGPS, AdisInsight) with study details for the 3\u2011month MSDC\u20110160 AD feasibility study. \ue200cite\ue202turn0search6\ue202turn0search7\ue201."
    ]
}